Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Automated Cell Separation Achieved for Three Cell Types Simultaneously

By BiotechDaily International staff writers
Posted on 05 May 2014
Image: New LIAISON Ixt/Arrow CellSep Advanced provides rapid, automated cell separation for up to three cell types in a single run (Photo courtesy of DiaSorin).
Image: New LIAISON Ixt/Arrow CellSep Advanced provides rapid, automated cell separation for up to three cell types in a single run (Photo courtesy of DiaSorin).
The automated isolation of cells directly from whole blood or buffy coat is based on magnetic bead technology.

DiaSorin (Saluggia, Italy) has launched LIAISON Ixt/Arrow CellSep Advanced, which can isolate up to 3 cell types per sample in just 32 minutes per cell type, offering significant time savings compared to manual cell separation methods.

CellSep Advanced is designed for use on the LIAISON Ixt/Arrow instrument for the separation of 1, 2, or 3 cell types in up to 12 samples at a time. Requiring minimal hands-on intervention CellSep Advanced produces good yields of purified cell preparations ready for use in a wide range of downstream applications, including lineage-specific chimerism analysis. The Ixt/Arrow automated platform also minimizes human error and ensures reproducibility between runs for consistent and reliable downstream analysis.

The LIAISON Ixt/Arrow instrument can also be used for DNA extraction using the Ixt/Arrow Blood DNA extraction kit, ensuring streamlined processing of samples and, by reducing instrumentation requirements, saving valuable bench space in the laboratory.

DiaSorin is a leader in the field of biotechnology. For over 40 years the company has been developing, producing, and marketing reagent kits for in vitro diagnostics worldwide. With their most recent acquisition of the NorDiag Group, DiaSorin gains access to the nucleic acid isolation and cell separation markets. Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently (private diagnostic services laboratories) can meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology, and endocrinology.

Related Links:

DiaSorin



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.